The global incidence of dengue has increased sevenfold between 1990 and 2013. Despite a low case fatality rate (<1%), during epidemics, due to the large number of people affected, overall mortality rates can be significant. The risk of clinically significant bleeding in dengue is unpredictable and often contributes to an adverse outcome. This systematic review focuses on the evidence for prophylactic and therapeutic interventions for bleeding in dengue infection. PubMed, CINAHL, Cochrane Library, Embase and Google Scholar were searched for randomized, quasi-randomized and non-randomized, prospective or retrospective studies that had a control group alongside an intervention aimed at stopping or preventing bleeding in dengue infection. Eleven studies that included 1904 patients in 12 study arms were eligible. These assessed the role of platelet transfusion [two randomized controlled trials (RCTs) and three non-randomized studies], plasma transfusion (one RCT), recombinant activated factor VII (one RCT), anti-D globulin (two RCTs), immunoglobulin (one RCT) and interleukin 11 (one RCT) as prevention or treatment for bleeding. Due to significant heterogeneity in study design and outcome reporting, a meta-analysis was not performed. Currently there is no evidence that any of the above interventions would have a beneficial effect in preventing or treating clinically significant bleeding in dengue.
Introduction
Dengue is a flavivirus infection transmitted by Aedes mosquitoes. It is a disease with global implications and results in considerable morbidity and mortality. Transmission occurs in at least 128 countries and almost 4 billion people are at risk. 1 The total number of recorded cases of dengue has increased exponentially, from less than a thousand cases per year globally in the 1950s to an annual incidence of 58.4 million cases in 2013. South and South-east Asia account for a major proportion of the global burden of dengue, with an estimated mortality of 1.29 and 8.49 per million population, respectively, in 2013. 2 Dengue encompasses a clinical spectrum of disease, from simple dengue fever, to severe disease characterized by thrombocytopaenia, plasma leakage, bleeding and multi-organ dysfunction. The most striking manifestation of dengue infection is the plasma leakage syndrome, which, when severe, leads to shock. In extreme cases, multi-organ dysfunction syndrome occurs, leading to death. Although the term 'dengue haemorrhagic fever' is commonly used to denote severe disease, plasma leakage and not haemorrhage is the hallmark of severe dengue.
Nonetheless, haemorrhage does occur. Bleeding manifestations in dengue range from minor cutaneous and mucosal bleeding to deep visceral bleeding, including intracranial, pulmonary, gastrointestinal and intraperitoneal haemorrhage. Bleeding manifestations in dengue are seen in 20-60% of hospitalized patients in different case series. [3] [4] [5] Although severe bleeding is generally considered an unusual manifestation of dengue, 4 bleeding is responsible for a significant proportion of fatal outcomes. For example, in a nationwide retrospective death review in Malaysia from 2013 to 2014, severe bleeding was responsible for 29.7% of deaths. 6 The exact pathophysiological mechanism behind bleeding in patients with dengue infection has not been clearly elucidated. Several haemostatic abnormalities have been described in patients with dengue, which in combination might predispose to bleeding. Severe thrombocytopaenia, prolonged prothrombin time (PT), prolonged activated partial thromboplastin time (aPTT), prolonged thrombin time (TT), reduction of certain coagulation factors, increased tissue factor level, alterations in the fibrinolytic system and reduced protein C and protein S levels are some of the abnormalities reported in the literature. [7] [8] [9] It is also recognized that most of these haemostatic abnormalities spontaneously resolve without any clinically significant bleeding. 7, 10 On the other hand, major bleeding manifestations in dengue do not necessarily correlate with coagulation abnormalities. 11 In particular, the degree of thrombocytopaenia does not closely relate to the risk and severity of bleeding in dengue. 12, 13 Thus coagulation parameters may not be a useful guide for determining the risk of bleeding in dengue. Furthermore, there is no consensus in the guidelines as to whether, or when, correction of thrombocytopaenia or deranged coagulation parameters should be attempted. 14, 15 Since thrombocytopaenia is the most striking abnormality seen in dengue patients, platelet transfusion has been widely used, both prophylactically as well therapeutically, in managing dengue patients in the past, based on the assumption that thrombocytopaenia is a significant contributor towards haemorrhage. 16, 17 This practice has declined over the years. Various other therapeutic agents aimed at preventing or reducing bleeding have been studied, including recombinant activated factor VII (rFVIIa), anti-D globulin and intravenous immunoglobulin (IVIg), among others. At present, the guidelines for the management of dengue do not recommend the use of any therapeutic agent for prevention or treatment of bleeding. 14, 15 We conducted a systematic review to determine the efficacy and safety of prophylactic and therapeutic measures used to manage bleeding in dengue infection.
Materials and methods
This review includes randomized, quasi-randomized or nonrandomized, prospective or retrospective studies that had a control group looking at interventions for bleeding manifestations in dengue. We searched PubMed, Embase, CINAHL, Cochrane Library and Google Scholar using the search terms 'bleeding' OR 'hemorrhage' OR 'haemorrhage' AND 'dengue' in the title or abstract fields with no restriction on date limits. References provided in full papers were also used to identify additional papers for review. Only articles published in English were included. The last date of the search was 3 July 2017. The review is registered with PROSPERO (CRD42017074419).
Two reviewers (NLdS and PW) independently screened the abstracts and selected articles to assess the full text articles. Eligible studies were finalized by consensus among all authors. Data from individual studies were extracted using a customized data extraction pro forma designed by the authors. The data items extracted from each eligible study included the location of the trial, participant demographics, patient characteristics of the test and control groups, severity of disease, details of intervention and outcome measures. The primary outcome measure we considered was documented episodes of bleeding following the intervention. Secondary outcome measures considered were adverse events and mortality. Some studies also report the platelet count and need for platelet transfusions as an indication of treatment efficacy. Although there is currently no evidence to link platelet count to bleeding risk in dengue, for the sake of completeness we included studies where an outcome measure was improvement in platelets, as a possible surrogate marker for prevention of bleeding. Of the included studies, randomized controlled trials (RCTs) were examined qualitatively for risks of bias based on the Cochrane risk of bias assessment tool. 18 Quality scores for individual studies were not calculated, as it is not perceived by all as an objective measure of risk of bias. 19 Meta-analysis could not be performed due to study heterogeneity, and publication bias was not assessed due to the small number of available studies for each comparison.
Results
The initial search yielded 676 results. After screening of abstracts, 20 potential papers were identified. After excluding uncontrolled studies, case reports, small case series and reviews, nine papers remained. Another two papers were identified by cross-referencing. The PRISMA flow diagram for study selection is shown in Figure 1 . Of the 11 studies, 5 studies on platelet transfusion (2 RCTs and 3 non-randomized studies), 1 RCT on plasma transfusion, 1 RCT on recombinant activated factor VII, 2 RCTs on intravenous anti-D globulin, 1 RCT on IVIg and 1 RCT on interleukin 11 (IL-11) were selected for further evaluation. The reviewers' assessment of risk of bias is summarized in Figure 2 .
Platelet and plasma transfusion

RCTs
The first RCT on platelet transfusion in dengue was a singlecentre non-blinded study conducted in 2011 in Pakistan. 20 The primary outcome measure considered by the investigators was an increase in platelet count; a reduction in clinical bleeding was the secondary outcome. Adult patients with dengue and a Figure 1 . PRISMA diagram of the systematic review. We searched PubMed, Embase, CINAHL, Cochrane Library and Google Scholar using the search terms 'bleeding' OR 'hemorrhage' OR 'haemorrhage' AND 'dengue' in the title or abstract fields with no restriction on date limits. This yielded 676 results. After screening of abstracts, 20 potential papers were identified. After excluding uncontrolled studies, case reports, small case series and reviews, nine papers remained. References provided in full papers were also used to identify additional papers for review. Another two papers were identified by this method. A total of 11 studies were reviewed for this article.
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platelet count <30 000/μl without bleeding manifestations or with mild bleeding were included. In this study, the method of randomization and measures for allocation concealment were not specified and therefore the risk of selection bias is unclear. The study was non-blinded and therefore was at risk of having performance and detection bias; however, since the outcome measures were objective, these factors may not have had a significant effect on the final results. Nineteen patients (46.4%) were considered responders, based on the platelet increase 1 h after transfusion (post-transfusion platelet increment >10 000/μl or corrected count increment >50 000/μl). Although platelet transfusion increased platelet counts, this did not result in a significant difference in progression to severe bleeding, time needed for cessation of bleeding or a reduction in new-onset bleeding; notably, there was only one patient (in the treatment group), thus conclusions on the effects of bleeding cannot be clearly made from this study. Platelet transfusion-related complications were experienced by three (7%) patients.
The second study, a multicentre RCT on prophylactic platelet transfusion in dengue, recruited 372 adult patients with dengue and platelet counts <20 000/μl, without significant bleeding, between 2010 and 2014 in Malaysia and Singapore. 21 Patients with comorbidities such as chronic liver and kidney disease, active peptic ulcer disease, anticoagulant use, haematological diseases and critically ill patients were excluded from the study. The primary endpoint was clinical bleeding, excluding petechiae. The randomization method described in this study was strong, resulting in a low risk of selection bias. The outcome measures were objective, hence the effect of lack of blinding is likely to have been low. The analysis was based on intention to treat (ITT) and the risk of attrition bias was low. Platelet transfusion was not shown to be superior to supportive care in preventing clinical bleeding and was associated with 13 adverse events, compared with 2 adverse events in the control group (relative risk 6.26 [95% confidence interval 1.43 to 27.34]). The mean time to recovery of platelet count >50 000/μl was not significantly different between the two groups. Notably, in this cohort of patients, plasma leakage occurred in only 13% (47/369) of patients, which is lower than the figures reported in other hospitalized cohorts.
22, 23 The generalizability of these results to patients with severe dengue with the potential towards a higher incidence of significant bleeding is questionable.
The effects of fresh frozen plasma (FFP) on platelet counts in dengue were evaluated in a RCT in 2008 in Sri Lanka. 24 The trial randomized 109 adult dengue patients with platelet counts of 10 000-40 000/μl to receive 3 units of FFP or normal saline as placebo. The primary outcome measures were an increase in platelet counts at 12, 24 and 48 h post-transfusion. The randomization method was sound, with a low risk selection bias. Although the study was described as a blinded study, measures taken towards blinding appear inadequate, resulting in a high risk of performance bias. Nonetheless, like in the other studies mentioned above, the objective nature of the outcome measures minimizes the impact of this. Statistical analysis was done using ITT analysis and bias due to incomplete data was minimized. Platelet counts increased in patients receiving FFP at 12 h, with 31 400/μl (SD 37 000) in the treatment group and 18 000/μl (SD 26 500) in the control group (p=0.04). However, this increase was not sustained at 24 and 48 h. Notably, bleeding was not an outcome measure in this study, and the fact that platelet counts improved may not correlate with prevention of bleeding. One patient in the intervention group developed an anaphylactic reaction to FFP. A detailed breakdown of other adverse events was not provided.
Non-randomized comparative studies
A retrospective study from Malaysia compared 106 paediatric patients presenting between 1991 and 2000 with complicated dengue fever, including dengue shock syndrome, who received platelets or FFP transfusion (n=53) or no intervention (n=53). 25 Patients with clinically significant bleeding (evidenced by low/ normal haematocrit) were excluded. While no reduction in Figure 2 . Risk of bias graph. Eight RCTs are included in the risk of bias summary diagram. Only two studies have a clear description of methods of randomization so that selection bias is effectively minimized. Although some studies have a high risk of performance and detection bias due to a lack of blinding or a poor mechanism of blinding, outcome assessment was not affected in most of the studies. Except for two studies, all the other studies either had no loss of data or used ITT analysis. As a result, attrition bias is minimized. A single-centre retrospective analysis of patients with dengue in Singapore in 2004 included 256 patients whose platelet count was <20 000/mm 3 who had no clinical bleeding. 12 There was no benefit seen in patients receiving platelet transfusions in terms of clinical bleeding, increment in platelet counts, time to recovery of platelet counts to >50 000/μl or length of hospital stay. One patient in the group given platelet transfusions died of major gastrointestinal bleeding and two patients among those who did not receive platelets developed minor bleeding. The decision to transfuse platelets was made based on the treating clinicians' judgement, without any predetermined guidelines or protocols.
Another retrospective observational study in Singapore evaluated the clinical outcome of prophylactic platelet transfusion in patients with dengue and platelet counts <20 000/μl. 26 There were 788 eligible patients for analysis and 486 received prophylactic transfusions. Outcome variables were compared with 302 patients who did not receive platelet transfusions. Recovery of thrombocytopaenia was higher in those who received transfusions. The increment in platelet counts was 8000/μl (95% CI −6000 to 43 000) in the transfused group compared with 5000/μl (95% CI −6000 to 31 000) in the non-transfused group (p<0.0001). The median length of hospital stay was 6 d (95% CI 4-8) in transfused group and 5 d (95% CI 5-7) in the nontransfused group (p<0.0001). Eighty-nine patients (18.3%) in the transfused group and 28 patients (9.3%) of those not transfused developed mucosal bleeding (p=0.001). There were many baseline differences in the study groups that might have resulted in bias; there were higher numbers of patients with severe dengue, severe bleeding or plasma leakage in the group receiving platelet transfusion; liver enzymes were higher and white cell counts and platelet counts were lower in this group. Since transfusions were given based on the treating clinicians judgement, it is possible that the threshold for transfusion was lower in patients who were more sick. To correct for this, the investigators performed a propensity score matching analysis that showed there was no difference in clinical bleeding, mucosal bleeding or internal bleeding between the two groups after adjustment for variables that may have influenced the treating clinicians' decision to transfuse platelets.
rFVIIa
RCTs on rFVIIa
The effect of rFVIIa was studied in an RCT of children with dengue haemorrhagic fever grade II-III with active bleeding in Thailand and the Phillipines. 27 The primary outcome was response of bleeding. If bleeding completely stopped, treatment was considered effective, if partially controlled it was considered partially effective and if it remained the same or worsened, treatment was considered ineffective. The method of randomization is not clearly mentioned in this study. The study was blinded and performance bias was prevented by providing an identical-looking placebo. However, there is the possibility of detection bias since authors have not clearly described the measures taken to blind the investigators who assessed clinical outcomes. At 2 h after administration, the control of bleeding improved in the treatment group. An effective response to bleeding was seen at 2 h in 12/16 (75%) patients in the intervention group and 4/9 (44.4%) in the control group, but subsequently no difference was seen. Platelet transfusions were given more often in the control group (33.3%) compared with the treatment group (6.3%). Red cell and plasma transfusions were not different between the two groups. The study had a sample size of 25 and had minor violations in protocol in relation to the timing of repeat administrations of rFVIIa. Overall, this study shows no evidence of benefit with rFVIIa for bleeding in dengue.
Non-randomized comparative studies
There were no observational studies of rFVIIa with a control group.
Intravenous anti-D globulin
RCTs on anti-D globulin
In an RCT published from the Philippines in 2007 that studied the response of thrombocytopaenia to anti-D globulin injection in patients with dengue haemorrhagic fever, beneficial effects were shown in terms of improvement of thrombocytopaenia. 28 Adult and paediatric patients with dengue haemorrhagic fever were randomized to receive either anti-D globulin or placebo and platelet counts were monitored. The outcome measure was an increase in platelet count. The method of randomization was not specified in this paper. Double-blinding was done effectively, preventing performance and detection bias. All recruited patients were included in the analysis. Of 47 patients recruited, only 24 had platelet counts <50 000/μl, and in this group a greater increase in platelet count was seen in those receiving anti-D globulin (n=12); this difference was not seen in those with platelet counts >50 000/μl. There were two deaths, one each from the treatment and placebo groups.
Another RCT from India conducted in 2010 showed that administration of anti-D globulin resulted in an increase in platelet count as well as a reduction in bleeding. 29 Patients with dengue and platelet counts <20 000/μl were enrolled into the study. Fifteen patients with no bleeding or mild bleeding were included in each group. In the intervention group, anti-D globulin was administered in addition to standard supportive care and platelet transfusion. Random sequence generation was done using a computer-based system, however, it is not clear whether they used precautions to maintain allocation concealment. The study was not blinded. All included patients were analysed, resulting in low attrition bias. Platelet transfusion requirements were lower in the intervention group (187 vs 342 ml; p=0.01). However, the indication or justification for platelet transfusion is not clear in the methodology and we do not consider this as a valid outcome measure based on the results in the previous section. Grade I bleeding, which was present in five patients in the intervention group, reduced to zero at 48 h, whereas in the control group the reduction was from six to five (p=0.014). Similarly, grade II bleeding was significantly S. Rajapakse et al. reduced at 24 h (five to zero and seven to four in the intervention and control groups, respectively; p=0.032). At other time intervals considered, differences were not significant. There were no deaths, and no serious complications were reported. No patients required red cell transfusion.
Non-randomized comparative studies
There were no observational studies with a control group evaluating the role of anti-D globulin in dengue.
IVIg
RCTs on IVIg
There is only one RCT on the effect of IVIg on thrombocytopaenia in dengue infection. 30 This study from the Philippines in 2007 included 31 patients with platelet counts of 20 000-80 000/μl without clinical evidence of bleeding who were randomized to receive IVIg or placebo. The outcome measure was an increase in platelet count and no clinical bleeding. It is unclear at which point the randomization was done, and there were more patients with dengue haemorrhagic fever in the control group. This was not a blinded study. Whether there was a loss of data prior to analysis is unclear. No difference in platelet counts were seen in the two groups.
Non-randomized comparative studies
There are no observational studies on the use of IVIg in dengue.
Tranexamic acid
Tranexamic acid is an anti-fibrinolytic agent that preserves and stabilizes fibrin's matrix structure and thereby helps to control bleeding. Its use is recommended in some guidelines 14 to mitigate menstrual bleeding and gastrointestinal bleeding. There are no controlled studies on its use in dengue.
Recombinant human IL-11
RCTs on IL-11
A RCT from Pakistan enrolling 40 adult patients evaluated the effect of recombinant human IL-11 in patients with dengue with platelet counts of 10 000-30 000/μl without clinical bleeding. 31 The method of randomization in the study is unclear. Blinding was done effectively, thus the risks of performance and detection bias are low. All included patients were analysed, without any attrition bias. 
Non-randomized comparative studies
There were no observational studies on the role of recombinant human IL-11 in dengue.
Discussion
There is no trial evidence, or evidence from observational studies, to support the use of platelet transfusion or plasma transfusion to prevent clinically significant bleeding in patients with dengue infection and thrombocytopaenia. Data from observational studies are fraught with problems, however, because of the lack of clear guidelines regarding the indications for platelet transfusion. In the past, platelet transfusions were given freely, based on clinical judgment, at various thresholds. 17 There is no evidence of benefit in using platelet transfusions and hence most current guidelines do not recommend the use of platelet transfusion in dengue, 14 and indeed, in the light of emerging evidence demonstrating the lack of benefit, the practice of routinely transfusing platelets when counts drop below a certain threshold has decreased over the years. Conversely, studies of a restrictive strategy for platelet transfusion in dengue with thrombocytopaenia have shown that such restrictive strategies have no adverse effect on outcome. 17, 32 Notably, the two RCTs on platelet transfusion 20, 21 were on patients with severe thrombocytopaenia but less severe disease. Thrombocytopaenia does not correlate with bleeding risk, 12, 13 nor is there evidence to show that it correlates with the severity of dengue-in particular, the occurrence of plasma leakage. There is definite evidence of increased risk of adverse effects, particularly allergic reactions, with the use of platelet transfusion. The evidence of benefit in terms of platelet count with transfusion of FFP is limited and does not translate into a reduction of clinical bleeding.
The pathophysiological relationship between thrombocytopaenia and bleeding in dengue is not clearly understood. Thrombocytopaenia in dengue is due to several causes and its pathogenesis is complex. Bone marrow suppression, evidenced by hypocellularity and attenuation of megakaryocyte maturation, 33 together with peripheral destruction of platelets through activation of the complement cascade, antibody-mediated lysis and phagocytosis 34, 35 occur. Platelet dysfunction is also known to take place. 34 Bleeding in dengue, on the other hand, is multifactorial, and platelets may play only a small part in its pathogenesis, and associated coagulopathy and vascular damage are important contributors. 36 This may explain why the correlation between platelet count and bleeding is poor.
The fact remains that there is little trial evidence on the role of platelet transfusion in patients with thrombocytopaenia and moderate to severe bleeding. There is clearly a need for further study on this. Currently the guidelines recommend administration of fresh packed cells or fresh whole blood in patients who have moderate to severe bleeding in dengue. 14, 15 There are currently no published studies evaluating the place of blood transfusion in this situation.
Administration of rFVIIa may result in short-term improvement in control of bleeding in patients with dengue and active bleeding but shows no overall benefit. Its high cost limits its use, estimated at around US$4241 per additional quality adjusted life year. 37 It may be of benefit in patients with severe bleeding, as a short-term measure. Intravenous anti-D globulin has shown some evidence of benefit in increasing platelet Transactions of the Royal Society of Tropical Medicine and Hygiene counts in patients with dengue, although the impact on clinical bleeding is unclear. There is no evidence of benefit with the use of IVIg with regards to improvement in platelet count or reduction in bleeding, and there is no justification to use this therapeutic agent in the treatment of dengue infection. 38 The single randomized study on IL-11 showed no effect on clinical bleeding and its use cannot be recommended. There is no trial evidence to support or refute the use of tranexamic acid.
It is noteworthy that almost all studies looked at prevention or minimizing bleeding; there were no studies that examined the place of any of these measures in the management of severe haemorrhage. In the absence of evidence, it is likely that clinicians will continue to use platelets, FFP and blood, as well as other measures such as tranexamic acid and rFVIIa, in the setting of severe haemorrhage.
Conclusions
(1) Prophylactic platelet transfusion should not be routinely prescribed in patients with dengue with no bleeding based on low platelet count. (2) Therapeutic platelet transfusion should not be routinely prescribed in patients with dengue with thrombocytopaenia and mild bleeding. (3) There is inadequate evidence to support or refute the use of platelet transfusion in patients with severe bleeding in dengue. (4) There is a need for further, well-designed RCTs to evaluate the role of platelets and plasma transfusion in patients in both the prevention of bleeding and in the setting of clinically significant bleeding in dengue infection. (5) There is currently insufficient evidence regarding the role of rFVIIa, anti-D globulin, Ig or tranexamic acid in the prevention or treatment of bleeding in dengue infection and there is a place for further research on these therapeutic agents.
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